Patents by Inventor Gabriele PSZOLLA
Gabriele PSZOLLA has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20240117068Abstract: The present invention concerns antigen binding proteins specifically binding melanoma associated antigen A (MAGE-A) protein-derived antigens. The invention in particular provides antigen binding proteins which specifically bind to the MAGE-A antigenic peptide comprising or consisting of SEQ ID NO: 1 in a complex with a major histocombatibility (MHC) protein. The antigen binding proteins of the invention contain, in particular, the complementary determining regions (CDRs) of novel engineered T cell receptors (TCRs) that specifically bind to said MAGE-A peptide/MHC complex. The antigen binding proteins of the invention are of use for the diagnosis, treatment and prevention of MAGE-A expressing cancerous diseases. Further provided are nucleic acids encoding the antigen binding proteins of the invention, vectors comprising these nucleic acids, recombinant cells expressing the antigen binding proteins and pharmaceutical compositions comprising the antigen binding proteins of the invention.Type: ApplicationFiled: December 13, 2023Publication date: April 11, 2024Inventors: Meike HUTT, Felix UNVERDORBEN, Sebastian BUNK, Dominik MAURER, Martin HOFMANN, Gabriele PSZOLLA, Sara YOUSEF, Claudia WAGNER, Frank SCHWOEBEL, Heiko SCHUSTER
-
Publication number: 20240092933Abstract: The present invention concerns antigen binding proteins directed against PRAME protein-derived antigens. The invention in particular provides antigen binding proteins which are specific for the tumor expressed antigen PRAME, wherein the tumor antigen comprises or consists of SEQ ID NO: 50 and is in a complex with a major histocompatibility complex (MHC) protein. The antigen binding proteins of the invention contain, in particular, the complementary determining regions (CDRs) of novel engineered T cell receptors (TCRs) that specifically bind to said PRAME peptide. The antigen binding proteins of the invention are for use in the diagnosis, treatment and prevention of PRAME expressing cancerous diseases. Further provided are nucleic acids encoding the antigen binding proteins of the invention, vectors comprising said nucleic acids, recombinant cells expressing the antigen binding proteins and pharmaceutical compositions comprising the antigen binding proteins of the invention.Type: ApplicationFiled: November 16, 2023Publication date: March 21, 2024Inventors: Gabriele PSZOLLA, Martin HOFMANN, Meike HUTT, Sebastian BUNK, Felix UNVERDORBEN, Frank SCHWOEBEL, Dominik MAURER, Maike JAWORSKI, Claudia WAGNER, Florian SCHWOERER, Heiko SCHUSTER
-
Publication number: 20240052054Abstract: The present invention concerns antigen binding proteins specifically binding melanoma associated antigen A (MAGE-A) protein-derived antigens. The invention in particular provides antigen binding proteins which specifically bind to the MAGE-A antigenic peptide comprising or consisting of SEQ ID NO: 1 in a complex with a major histocombatibility (MHC) protein. The antigen binding proteins of the invention contain, in particular, the complementary determining regions (CDRs) of novel engineered T cell receptors (TCRs) that specifically bind to said MAGE-A peptide/MHC complex. The antigen binding proteins of the invention are of use for the diagnosis, treatment and prevention of MAGE-A expressing cancerous diseases. Further provided are nucleic acids encoding the antigen binding proteins of the invention, vectors comprising these nucleic acids, recombinant cells expressing the antigen binding proteins and pharmaceutical compositions comprising the antigen binding proteins of the invention.Type: ApplicationFiled: October 9, 2023Publication date: February 15, 2024Inventors: Meike HUTT, Felix UNVERDORBEN, Sebastian BUNK, Dominik MAURER, Martin HOFMANN, Gabriele PSZOLLA, Sara YOUSEF, Claudia WAGNER, Frank SCHWOEBEL, Heiko SCHUSTER
-
Patent number: 11859009Abstract: The present invention concerns antigen binding proteins directed against PRAME protein-derived antigens. The invention in particular provides antigen binding proteins which are specific for the tumor expressed antigen PRAME, wherein the tumor antigen comprises or consists of SEQ ID NO: 50 and is in a complex with a major histocompatibility complex (MHC) protein. The antigen binding proteins of the invention contain, in particular, the complementary determining regions (CDRs) of novel engineered T cell receptors (TCRs) that specifically bind to said PRAME peptide. The antigen binding proteins of the invention are for use in the diagnosis, treatment and prevention of PRAME expressing cancerous diseases. Further provided are nucleic acids encoding the antigen binding proteins of the invention, vectors comprising said nucleic acids, recombinant cells expressing the antigen binding proteins and pharmaceutical compositions comprising the antigen binding proteins of the invention.Type: GrantFiled: September 22, 2022Date of Patent: January 2, 2024Assignee: IMMATICS BIOTECHNOLOGIES GMBHInventors: Gabriele Pszolla, Martin Hofmann, Meike Hutt, Sebastian Bunk, Felix Unverdorben, Frank Schwoebel, Dominik Maurer, Maike Jaworski, Claudia Wagner, Florian Schwoerer, Heiko Schuster
-
Patent number: 11840577Abstract: The present invention concerns antigen binding proteins specifically binding melanoma associated antigen A (MAGE-A) protein-derived antigens. The invention in particular provides antigen binding proteins which specifically bind to the MAGE-A antigenic peptide comprising or consisting of SEQ ID NO: 1 in a complex with a major histocombatibility (MHC) protein. The antigen binding proteins of the invention contain, in particular, the complementary determining regions (CDRs) of novel engineered T cell receptors (TCRs) that specifically bind to said MAGE-A peptide/MHC complex. The antigen binding proteins of the invention are of use for the diagnosis, treatment and prevention of MAGE-A expressing cancerous diseases. Further provided are nucleic acids encoding the antigen binding proteins of the invention, vectors comprising these nucleic acids, recombinant cells expressing the antigen binding proteins and pharmaceutical compositions comprising the antigen binding proteins of the invention.Type: GrantFiled: July 30, 2020Date of Patent: December 12, 2023Assignee: IMMATICS BIOTECHNOLOGIES GMBHInventors: Meike Hutt, Felix Unverdorben, Sebastian Bunk, Dominik Maurer, Martin Hofmann, Gabriele Pszolla, Sara Yousef, Claudia Wagner, Frank Schwoebel, Heiko Schuster
-
Publication number: 20230357428Abstract: The present invention concerns antigen binding proteins directed against PRAME protein-derived antigens. The invention in particular provides antigen binding proteins which are specific for the tumor expressed antigen PRAME, wherein the tumor antigen comprises or consists of SEQ ID NO: 50 and is in a complex with a major histocompatibility complex (MHC) protein. The antigen binding proteins of the invention contain, in particular, the complementary determining regions (CDRs) of novel engineered T cell receptors (TCRs) that specifically bind to said PRAME peptide. The antigen binding proteins of the invention are for use in the diagnosis, treatment and prevention of PRAME expressing cancerous diseases. Further provided are nucleic acids encoding the antigen binding proteins of the invention, vectors comprising said nucleic acids, recombinant cells expressing the antigen binding proteins and pharmaceutical compositions comprising the antigen binding proteins of the invention.Type: ApplicationFiled: April 17, 2023Publication date: November 9, 2023Inventors: Gabriele PSZOLLA, Martin HOFMANN, Meike HUTT, Sebastian BUNK, Felix UNVERDORBEN, Frank SCHWOEBEL, Dominik MAURER, Maike JAWORSKI, Claudia WAGNER, Florian SCHWOERER, Heiko SCHUSTER
-
Publication number: 20230203200Abstract: The present invention concerns bispecific antigen binding proteins directed against MHC presented target antigens (TA). The invention in particular provides bispecific antigen binding proteins comprising at least two antigen binding sites (A and B), wherein the antigen binding site A binds to CD3 and the antigen binding site B binds to a target antigenic (TA) peptide/MHC complex. The bispecific antigen binding proteins of the invention comprise, in particular, the CDRs of the VL and VH domains of novel engineered anti-CD3 antibodies having a reduced affinity. The bispecific antigen binding proteins of the invention are of use for the diagnosis, treatment and prevention of TA associated diseases, such as tumor-associated antigen (TAA) expressing cancerous diseases.Type: ApplicationFiled: November 2, 2022Publication date: June 29, 2023Inventors: Gabriele PSZOLLA, Martin HOFMANN, Felix UNVERDORBEN, Meike HUTT, Dominik MAURER, Sebastian BUNK
-
Publication number: 20230132241Abstract: The present invention concerns antigen binding proteins directed against PRAME protein-derived antigens. The invention in particular provides antigen binding proteins which are selective and specific for the tumor expressed antigen PRAME, wherein the tumor antigen comprises or consists of SEQ ID NO: 8 and is in a complex with a major histocompatibility complex (MHC) protein. The antigen binding proteins of the invention contain, in particular, the complementary determining regions (CDRs) of novel engineered T cell receptors (TCRs) that specifically bind to said PRAME peptide. The antigen binding proteins of the invention are for use in the diagnosis, treatment and prevention of PRAME expressing cancerous diseases. Further provided are nucleic acids encoding the antigen binding proteins of the invention, vectors comprising said nucleic acids, recombinant cells expressing the antigen binding proteins and pharmaceutical compositions comprising the antigen binding proteins of the invention.Type: ApplicationFiled: January 15, 2020Publication date: April 27, 2023Inventors: Sebastian BUNK, Martin HOFMANN, Meike HUTT, Dominik MAURER, Gabriele PSZOLLA, Frank SCHWOEBEL, Felix UNVERDORBEN, Claudia WAGNER, Sara YOUSEF
-
Publication number: 20230091330Abstract: The present invention concerns antigen binding proteins directed against PRAME protein-derived antigens. The invention in particular provides antigen binding proteins which are specific for the tumor expressed antigen PRAME, wherein the tumor antigen comprises or consists of SEQ ID NO: 50 and is in a complex with a major histocompatibility complex (MHC) protein. The antigen binding proteins of the invention contain, in particular, the complementary determining regions (CDRs) of novel engineered T cell receptors (TCRs) that specifically bind to said PRAME peptide. The antigen binding proteins of the invention are for use in the diagnosis, treatment and prevention of PRAME expressing cancerous diseases. Further provided are nucleic acids encoding the antigen binding proteins of the invention, vectors comprising said nucleic acids, recombinant cells expressing the antigen binding proteins and pharmaceutical compositions comprising the antigen binding proteins of the invention.Type: ApplicationFiled: September 22, 2022Publication date: March 23, 2023Inventors: Gabriele PSZOLLA, Martin HOFMANN, Meike HUTT, Sebastian BUNK, Felix UNVERDORBEN, Frank SCHWOEBEL, Dominik MAURER, Maike JAWORSKI, Claudia WAGNER, Florian SCHWOERER, Heiko SCHUSTER
-
Publication number: 20220372165Abstract: The present invention concerns antigen binding proteins directed against PRAME protein-derived antigens. The invention in particular provides antigen binding proteins which are specific for the tumor expressed antigen PRAME, wherein the tumor antigen comprises or consists of SEQ ID NO: 50 and is in a complex with a major histocompatibility complex (MHC) protein. The antigen binding proteins of the invention contain, in particular, the complementary determining regions (CDRs) of novel engineered T cell receptors (TCRs) that specifically bind to said PRAME peptide. The antigen binding proteins of the invention are for use in the diagnosis, treatment and prevention of PRAME expressing cancerous diseases. Further provided are nucleic acids encoding the antigen binding proteins of the invention, vectors comprising said nucleic acids, recombinant cells expressing the antigen binding proteins and pharmaceutical compositions comprising the antigen binding proteins of the invention.Type: ApplicationFiled: May 4, 2022Publication date: November 24, 2022Inventors: Gabriele PSZOLLA, Martin HOFMANN, Meike HUTT, Sebastian BUNK, Felix UNVERDORBEN, Frank SCHWOEBEL, Dominik MAURER, Maike JAWORSKI, Claudia WAGNER, Florian SCHWOERER, Heiko SCHUSTER
-
Publication number: 20210032361Abstract: The present invention concerns antigen binding proteins specifically binding melanoma associated antigen A (MAGE-A) protein-derived antigens. The invention in particular provides antigen binding proteins which specifically bind to the MAGE-A antigenic peptide comprising or consisting of SEQ ID NO: 1 in a complex with a major histocombatibility (MHC) protein. The antigen binding proteins of the invention contain, in particular, the complementary determining regions (CDRs) of novel engineered T cell receptors (TCRs) that specifically bind to said MAGE-A peptide/MHC complex. The antigen binding proteins of the invention are of use for the diagnosis, treatment and prevention of MAGE-A expressing cancerous diseases. Further provided are nucleic acids encoding the antigen binding proteins of the invention, vectors comprising these nucleic acids, recombinant cells expressing the antigen binding proteins and pharmaceutical compositions comprising the antigen binding proteins of the invention.Type: ApplicationFiled: July 30, 2020Publication date: February 4, 2021Inventors: Meike HUTT, Felix UNVERDORBEN, Sebastian BUNK, Dominik MAURER, Martin HOFMANN, Gabriele PSZOLLA, Sara YOUSEF, Claudia WAGNER, Frank SCHWOEBEL, Heiko SCHUSTER
-
Publication number: 20210032370Abstract: The present invention concerns bispecific antigen binding proteins directed against MHC presented target antigens (TA). The invention in particular provides bispecific antigen binding proteins comprising at least two antigen binding sites (A and B), wherein the antigen binding site A binds to CD3 and the antigen binding site B binds to a target antigenic (TA) peptide/MHC complex. The bispecific antigen binding proteins of the invention comprise, in particular, the CDRs of the VL and VH domains of novel engineered anti-CD3 antibodies having a reduced affinity. The bispecific antigen binding proteins of the invention are of use for the diagnosis, treatment and prevention of TA associated diseases, such as tumor-associated antigen (TAA) expressing cancerous diseases.Type: ApplicationFiled: July 30, 2020Publication date: February 4, 2021Inventors: Gabriele PSZOLLA, Martin HOFMANN, Felix UNVERDORBEN, Meike HUTT, Dominik MAURER, Sebastian BUNK
-
Patent number: 10665324Abstract: A method for constructing a library of amino-acid sequences having a common structural fold, and a method for designing and selecting an amino-acid sequence having a desired affinity to a molecular surface of interest of a molecular entity, using the library, are provided herein. The methods are based on a stochastic sampling of backbone conformations and amino acid conservation patterns observed in experimentally available protein structures having the common structural fold.Type: GrantFiled: July 6, 2015Date of Patent: May 26, 2020Assignee: Yeda Research and Development Co. Ltd.Inventors: Sarel Fleishman, Gideon Lapidoth, Maria Gabriele Pszolla, Christoffer Norn
-
Publication number: 20170206308Abstract: A method for constructing a library of amino-acid sequences having a common structural fold, and a method for designing and selecting an amino-acid sequence having a desired affinity to a molecular surface of interest of a molecular entity, using the library, are provided herein. The methods are based on a stochastic sampling of backbone conformations and amino acid conservation patterns observed in experimentally available protein structures having the common structural fold.Type: ApplicationFiled: July 6, 2015Publication date: July 20, 2017Inventors: Sarel FLEISHMAN, Gideon LAPIDOTH, Maria Gabriele PSZOLLA, Christoffer NORN